Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
about
Dry eye: an inflammatory ocular diseaseDesign of a superior cytokine antagonist for topical ophthalmic useTopical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with Sjögren's syndromeThe core mechanism of dry eye disease is inflammation.Dry eye as a mucosal autoimmune disease.Hevin plays a pivotal role in corneal wound healing.Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence.Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye diseaseIL-1β promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-κB- and AP-1-dependent pathways.Inflammatory Response to Lipopolysaccharide on the Ocular Surface in a Murine Dry Eye Model.Spdef null mice lack conjunctival goblet cells and provide a model of dry eye.Dry eye modifies the thermal and menthol responses in rat corneal primary afferent cool cells.Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?Lymphatic vessels: new targets for the treatment of inflammatory diseases.An update on dry eye disease molecular treatment: advances in drug pipelines.The eye: a window of opportunity in rheumatoid arthritis?Current Approach to Dry Eye Disease.Ageing and ocular surface immunity.Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsionTRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Dry eye syndrome: developments and lifitegrast in perspective.Reduction of product-related species during the fermentation and purification of a recombinant IL-1 receptor antagonist at the laboratory and pilot scale.Therapeutic inhibitors for the treatment of dry eye syndrome.The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases.MyD88 Deficiency Protects Against Dry Eye–Induced Damage.
P2860
Q26852044-43493019-19C4-4535-B836-A1ACE37F700EQ27676526-4F60B56A-D9A0-4711-86D2-9D19DF27129EQ34206399-E08B723F-C922-4D7E-883A-FA90DCE14787Q34473772-1141C6D6-37BF-406E-B8F3-10599C07067BQ34510429-8B6D04B8-5DA7-4DFB-B68B-6A74170D8129Q34647761-9F0AA319-AE48-4479-955D-41EF3CCA7287Q35058600-1A8F0877-07D9-4C5F-97F8-33AEC3682AF4Q35570541-F271BA51-FF55-4BA1-92A5-7A157AF57655Q35907009-760290F3-CA24-48C0-93D6-7A96B741B0CFQ36665694-1AFA279F-51BC-4C01-8BF7-DEFC17B1CC9FQ36872927-B8B7E3DC-44EF-40CE-BD58-178694B86DD2Q36986476-5ED7BAF0-A55F-46AD-810E-E1AB2CD27FBDQ37054835-1F9681B9-630B-4693-BC0D-634F47B4D867Q37195776-2F87AD56-154D-492D-B109-EDFEEBA1D25AQ37242107-4EC80BBD-F64E-4C3C-BD53-ECA9641118ABQ37397203-9A0FD06D-35DD-4727-B821-C5A347A1DA9AQ38161374-25FE3AA9-9226-44E3-B429-6A736C437AE6Q38207723-A4AECCE2-7534-4E15-A5CF-8C42495F00FEQ38219053-76F7BD5C-A6D5-4651-A62A-B07E60483A13Q38235721-C6E4D3D1-14A0-4069-860C-5D6D2FEB3B62Q38886086-B77760FD-CA42-472C-99E2-807345D5DAB0Q42792794-36CC6D67-9E65-4B73-940A-05B6271508ACQ47138569-FED62017-BC4C-439E-A6A7-A6C196A65872Q47442388-F7CEA6CE-7E9D-4F4C-86F8-30A7658B2EF0Q47639135-0582114C-3430-464B-8B9D-2269C5F92F96Q47861500-F1F76C6B-2FE2-4D4B-9A35-46F6B992100AQ50110517-380539E2-2A35-46B5-BB31-B9E45D9930BBQ52768652-4FDC71AF-E06B-4AA6-BDFD-751812900BC0Q55355486-C5B63D8B-8EED-4332-8DF7-BE4F40D18EB8
P2860
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@ast
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@en
type
label
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@ast
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@en
prefLabel
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@ast
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@en
P2093
P2860
P1476
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease
@en
P2093
Andre Okanobo
Mohammad H Dastjerdi
Shilpa Kodati
Sunil K Chauhan
P2860
P356
10.1016/J.AJO.2012.01.034
P407
P577
2012-04-26T00:00:00Z